​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health (GH) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $52.00, with a high of $52.00 and a low of $52.00. This represents a 6.08% increase from the last price of $49.02.

$15 $23 $31 $39 $47 $55 High: $52 Avg: $52 Low: $52 Last Closed Price: $49.02

GH Stock Rating

Guardant Health stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (96.15%), 0 Hold (0.00%), 1 Sell (3.85%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 25 Strong Sell Sell Hold Buy Strong Buy

GH Price Target Upside V Benchmarks

TypeNameUpside
StockGuardant Health6.08%
SectorHealthcare Stocks 23.68%
IndustryDiagnostics & Research Stocks22.21%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$42.50
Last Closing Price$49.02$49.02$49.02
Upside/Downside---13.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 257153--25
May, 256153--24
Apr, 256142--22
Mar, 256142--22
Feb, 257142--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2025Morgan Stanley$52.00$42.6621.89%6.08%
Aug 21, 2024Dan LeonardUBS$40.00$27.6844.51%-18.40%
Aug 08, 2024Bill BonelloCraig-Hallum$37.00$31.3717.95%-24.52%
Aug 08, 2024Tycho PetersonJefferies$40.00$33.9617.79%-18.40%
Jul 29, 2024Mark MassaroBTIG$50.00$35.2841.72%2.00%
Jun 28, 2024Subbu NambiGuggenheim$36.00$28.8824.65%-26.56%
Jun 04, 2024Kyle MiksonCanaccord Genuity$38.00$27.4138.64%-22.48%
Jun 03, 2024Tycho PetersonJefferies$32.00$27.1018.08%-34.72%
May 23, 2024Mark MassaroBTIG$45.00$22.5199.91%-8.20%
May 22, 2024Kyle MiksonCanaccord Genuity$30.00$23.0130.38%-38.80%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2025Piper SandlerOverweightOverweighthold
May 05, 2025ScotiabankOutperformOutperformhold
Mar 05, 2025Morgan StanleyOverweightOverweighthold
Jan 10, 2025BernsteinOutperformOutperformhold
Aug 21, 2024UBSBuyBuyhold
Aug 13, 2024Piper SandlerNeutralNeutralhold
Aug 08, 2024Cowen & Co.BuyBuyhold
Aug 08, 2024Craig-HallumBuyBuyhold
Aug 08, 2024JefferiesBuyBuyhold
Jul 29, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-3.80$-6.41$-4.28$-3.56----
Avg Forecast$-2.18$-4.26$-6.45$-3.58$-3.41$-2.90$-2.46$-2.32$-2.13
High Forecast$-2.10$-4.11$-6.26$-3.49$-3.32$-2.26$-1.18$-0.24$-2.04
Low Forecast$-2.23$-4.36$-6.80$-3.68$-3.50$-3.73$-2.99$-3.72$-2.29
Surprise %16.06%-10.80%-0.62%19.55%4.40%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$286.73M$373.65M$449.54M$563.95M$739.02M----
Avg Forecast$284.99M$364.29M$446.54M$558.07M$729.04M$846.27M$1.02B$1.23B$1.46B
High Forecast$289.97M$370.66M$464.85M$589.10M$729.24M$868.09M$1.02B$1.24B$1.54B
Low Forecast$277.20M$354.33M$435.97M$538.39M$728.83M$819.82M$1.02B$1.22B$1.41B
Surprise %0.61%2.57%0.67%1.05%1.37%----

Net Income Forecast

$-700M $-560M $-420M $-280M $-140M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-246.28M$-384.77M$-654.59M$-479.45M$-436.37M----
Avg Forecast$-221.25M$-372.37M$-508.71M$-479.45M$-382.22M$-364.59M$-312.67M$-168.64M$-238.87M
High Forecast$-177.00M$-297.90M$-406.97M$-383.56M$-372.11M$-252.82M$-132.14M$-27.21M$-227.92M
Low Forecast$-265.50M$-446.85M$-610.45M$-575.34M$-392.33M$-417.56M$-334.31M$-416.51M$-256.14M
Surprise %11.31%3.33%28.68%-14.17%----

GH Forecast FAQ

Is Guardant Health stock a buy?

Guardant Health stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Guardant Health is a favorable investment for most analysts.

What is Guardant Health's price target?

Guardant Health's price target, set by 26 Wall Street analysts, averages $52 over the next 12 months. The price target range spans from $52 at the low end to $52 at the high end, suggesting a potential 6.08% change from the previous closing price of $49.02.

How does Guardant Health stock forecast compare to its benchmarks?

Guardant Health's stock forecast shows a 6.08% upside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the diagnostics & research stocks industry (22.21%).

What is the breakdown of analyst ratings for Guardant Health over the past three months?

  • June 2025: 28.00% Strong Buy, 60.00% Buy, 12.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Guardant Health’s EPS forecast?

Guardant Health's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.9, marking a -18.54% decrease from the reported $-3.56 in 2024. Estimates for the following years are $-2.46 in 2026, $-2.32 in 2027, and $-2.13 in 2028.

What is Guardant Health’s revenue forecast?

Guardant Health's average annual revenue forecast for its fiscal year ending in December 2025 is $846.27M, reflecting a 14.51% increase from the reported $739.02M in 2024. The forecast for 2026 is $1.02B, followed by $1.23B for 2027, and $1.46B for 2028.

What is Guardant Health’s net income forecast?

Guardant Health's net income forecast for the fiscal year ending in December 2025 stands at $-365M, representing a -16.45% decrease from the reported $-436M in 2024. Projections indicate $-313M in 2026, $-169M in 2027, and $-239M in 2028.